Every 10-Q that ProMIS Neurosciences Inc. (PMN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMN filings page.
ProMIS Neurosciences Inc. reported a net loss of $11.7 million for the quarter and $20.0 million for the six months ended June 30, 2026, compared with losses of $10.1 million and $17.5 million in 2025. Operating expenses rose as the company advanced its lead Alzheimer’s antibody PMN310 and expanded its organization.
R&D spending reached $16.5 million for the first half of 2026, driven mainly by the Phase 1b PRECISE-AD trial, while G&A expenses increased to $4.4 million on higher compensation and professional fees. A January 2026 private placement provided $70.1 million of net proceeds, lifting cash to $53.4 million and total assets to $56.7 million with minimal liabilities of $7.3 million, resulting in positive shareholders’ equity of $49.4 million.
Management expects existing cash and short-term investments to fund operations and capital needs through 2027, while acknowledging continued losses and the need for additional capital to support future clinical activities beyond the current plan.
ProMIS Neurosciences Inc. reported a Q1 2026 net loss of $8.2 million, or $1.26 per share, compared with a $7.3 million loss a year earlier, as it ramped investment in its Alzheimer’s program PMN310. Research and development expenses rose to $7.0 million, including $6.3 million for PMN310, while general and administrative costs declined to $1.7 million.
In January 2026 the company strengthened its balance sheet with $70.1 million of net proceeds from a private placement of common shares, pre-funded warrants, and common share warrants, lifting cash to $63.8 million and total assets to $67.4 million as of March 31, 2026. Management now expects existing cash and short-term investments to fund operations through 2027.
The Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer’s disease has enrolled 144 patients across 21 U.S. sites. The study, which has FDA Fast Track designation, is designed to assess safety, amyloid-related imaging abnormalities, biomarkers, and early clinical outcomes, with a blinded interim analysis anticipated in early third quarter 2026 and top-line data expected in early 2027.
ProMIS Neurosciences Inc. reported Q3 2025 results, highlighting larger R&D investment and recent financings. The company posted a net loss of $11.6 million for the quarter and $29.0 million year-to-date. Total operating expenses were $11.8 million in Q3, driven mainly by PMN310 development costs. Cash was $15.4 million at September 30, 2025, with net cash used in operations of $18.8 million for the nine months.
Management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern. To bolster liquidity, ProMIS raised gross proceeds of $21.6 million in July 2025 through discounted warrant exercises, new warrants in private placements, and a registered direct pre-funded warrant sale, plus $0.7 million net via an at-the-market offering. Common Shares outstanding were 53,811,110 as of September 30, 2025, and also reported as outstanding as of November 12, 2025.
ProMIS Neurosciences (PMN) reported a cash balance of $4,510,119 and total assets of $9,509,496 at June 30, 2025, with a shareholders' deficit of $(382,578). The company recorded a net loss of $10,117,029 for the three months and $17,464,932 for the six months ended June 30, 2025, producing negative operating cash flow of $8,781,048 for the six-month period. Quarterly operating expenses were $10,184,661, driven by $8,050,610 of PMN310 development costs this quarter and $12,776,951 year-to-date. Accrued liabilities rose to $7,043,908 from $480,962 at year-end. Management discloses substantial doubt about the company’s ability to continue as a going concern without additional financing. Subsequent events in July 2025 include aggregate gross proceeds described as $21.6 million from various warrant transactions, an RD offering of approximately $0.8 million, PIPE commitments of $2.4 million and $3.0 million, and acceptance of discounted warrant exercises for approximately $15.9 million. PMN310 is in a Phase 1b multiple ascending dose study; all Cohort 1 patients are enrolled and Cohort 2 enrollment is >50% complete, and the FDA granted Fast Track designation to PMN310 on July 21, 2025.